HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Aug. 3, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that the Company's saliva-based NicAlert(TM) product successfully provided an on-the-spot evaluation of smoking status in an independent study of pregnant women in Alaska. Results from the study were recently presented at the 13th International Congress on Circumpolar Health in Novosibirsk, Russia. In the study, NicAlert(TM) and a highly sophisticated laboratory test, liquid chromatography tandem mass spectrometry (LC/MS/MS), were independently used to measure the levels of cotinine, a metabolite of nicotine, in saliva samples provided by 71 pregnant Alaska Native women. Based on the results, the researchers concluded that "NicAlert(TM) analysis of saliva samples is a rapid and useful method for classification of smokers versus nonsmokers among pregnant Alaska Native women."
